Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CERo Therapeutics Holdings ( (CERO) ) has issued an update.
On June 5, 2025, CERo Therapeutics Holdings completed an additional closing of its Series D Preferred Stock issuance, raising approximately $750,400 from institutional investors. This move is part of a broader $8 million financing effort, with proceeds intended to support FDA IND allowances in liquid and solid tumors and expand site activations. The company’s CEO highlighted this as a significant milestone in their clinical development, particularly for their novel CAR-T therapeutic candidate, CER-1236.
The most recent analyst rating on (CERO) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on CERo Therapeutics Holdings stock, see the CERO Stock Forecast page.
More about CERo Therapeutics Holdings
CERo Therapeutics Holdings, Inc. is an innovative immunotherapy company focused on developing next-generation engineered T cell therapeutics for cancer treatment. The company’s proprietary approach integrates both innate and adaptive immunity to create Chimeric Engulfment Receptor T cells (CER-T), which aim to eliminate tumors by employing phagocytic mechanisms. CERo’s lead product candidate, CER-1236, is in clinical trials for hematological malignancies.
Average Trading Volume: 1,976,176
Technical Sentiment Signal: Sell
Current Market Cap: $3.47M
See more data about CERO stock on TipRanks’ Stock Analysis page.